Myriad Genetics Inc (MYGN)

32.86
0.19 0.57
NASDAQ : Services
Prev Close 33.05
Open 32.92
Day Low/High 32.72 / 33.22
52 Wk Low/High 28.82 / 46.24
Volume 430.18K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 68.44M
Market Cap 2.25B
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Hereditary Cancer Risk Assessment Is An Important Option For Prostate Cancer Patients During Prostate Cancer Awareness Month

Hereditary Cancer Risk Assessment Is An Important Option For Prostate Cancer Patients During Prostate Cancer Awareness Month

Eligible Patients Can Use the myRisk® Hereditary Cancer Test to Help Improve Their Care and Potentially Prevent Cancer in Their Family Members

Myriad Launches RiskScore™ Beginning The Next Epoch In Hereditary Cancer Testing

Myriad Launches RiskScore™ Beginning The Next Epoch In Hereditary Cancer Testing

Provides Individualized Breast Cancer Risk for Patients Testing Negative with the myRisk® Hereditary Cancer Test

Short Interest Drops 10.8% For MYGN

Short Interest Drops 10.8% For MYGN

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 2,269,052 share decrease in total short interest for Myriad Genetics, Inc. , to 18,843,047, a decrease of 10.75% since 07/31/2017.

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

EndoPredict® Receives Positive Coverage Decisions From Medicare And Anthem

EndoPredict® Receives Positive Coverage Decisions From Medicare And Anthem

Brings Total Coverage to Over 90 Percent of Breast Cancer Patients

Crescendo Bioscience Announces Results From A Meta-Analysis Of Studies With Vectra® DA At The 2017 Annual European Congress Of Rheumatology

Data from >800 Patients Shows that a High Vectra DA Score is Associated with an Increased Risk of Joint Damage and Is More Predictive than Conventional Measures of RA

Crescendo Bioscience Announces Six Studies With Vectra® DA Will Be Presented At The 2017 Annual European Congress Of Rheumatology

Clinical Utility of Vectra® DA Further Demonstrated with New Data on Prediction of Joint Damage

Noteworthy Monday Option Activity: MYGN, MXWL, GIII

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Myriad Genetics, Inc. , where a total of 5,567 contracts have traded so far, representing approximately 556,700 underlying shares.

Myriad's BRACAnalysis CDx® Test Identified Patients With Metastatic Breast Cancer Who Benefited From Treatment With Olaparib In Phase 3 OlympiAD Study

Company to Seek FDA Approval of BRACAnalysis CDx Test in HER2- Metastatic Breast Cancer

Myriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™

Coverage Decisions Add 35 Million Additional Covered Lives Bringing Total to 109 Million

Myriad Genetics Announces Results From A Large 2,000 Patient Clinical Utility Study Of Its MyRisk® Hereditary Cancer Test At The 53rd Annual Meeting Of ASCO

50 Percent of Mutations Were Found in Patients Who Do Not Meet Current Testing Guidelines; 34 Percent of Mutations Were Identified In Unexpected Genes

Medicare Coverage Of Prolaris® Test Expands With The Addition Of Men Diagnosed With Favorable Intermediate Risk Prostate Cancer

Prolaris Now Accessible to 70 percent of Medicare Patients with Prostate Cancer

Myriad Genetics To Present Seven Studies At The 2017 American Society of Clinical Oncology Annual Meeting

Presentations Highlight Continued Advancements in Hereditary Cancer Panel Testing

Myriad Genetics' Prolaris® Test Accurately Predicts The 10-Year Risk Of Metastases In Men Treated For Prostate Cancer

Strong Predictive Power in Both African American and Non-African American Patients

Myriad Genetics To Present Results From Four Studies At The American Urological Association 2017 Annual Meeting

Featured Study Will Show Power of the Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.

Study Finds Wide Gap In Quality Of BRCA1/2 Variant Classification Between Myriad Genetics And A Common Public Database

26 Percent Discordance Rates Observed in Public Databases

Myriad Genetics And BeiGene Sign Agreement To Develop Companion Diagnostics For Use With BeiGene's Novel PARP Inhibitor, BGB-290

Collaboration Will Evaluate Myriad's myChoice® HRD and BRACAnalysis CDx® Tests

TheStreet Quant Rating: C (Hold)